血浆可溶性尿激酶型纤溶酶原激活剂受体在原发性局灶节段性肾小球硬化症患者病情评估中的作用  

Association of serum soluble urokinase plasminogen activator receptor levels in idiopathic focal segmental glomerulosclerosis patients＇ features evaluation

作　　者：李月红[1] 林则行 燕宇[2] 李松[2] 

机构地区：[1]清华大学医学中心 北京清华长庚医院肾内科,102218 [2]北京大学人民医院肾内科

出　　处：《临床内科杂志》2016年第3期181-184,共4页Journal of Clinical Internal Medicine

摘　　要：目的探讨血浆可溶性尿激酶型纤溶酶原激活剂受体（suPAR）在原发性局灶节段性肾小球硬化症（FSGS）患者病情评估中的作用。方法回顾性分析经肾活检诊断为原发性FSGS患者92例的临床和病理资料，酶联免疫吸附试验（ELISA）法测定肾活检前患者血浆suPAR水平，对血浆suPAR与原发性PSGS患者病情关系进行相关性分析。结果原发性FSGS占同期肾活检患者的5．2％，以肾病综合征为主要表现，非特殊型占60．9％，51～60岁发病率最高。原发性FSGs患者血浆suPAR在239—4458pg／ml，40岁以上患者水平偏高。Spearman相关性检验分析发现血浆suPAR与总胆固醇呈负相关。Logistic回归分析显示，血浆suPAR水平越高，第3个月及第6个月治疗完全缓解率越差。结论原发性FSGS以肾病综合征为主要表现，40岁以上患者血浆suPAR水平偏高，suPAR水平越高，治疗完全缓解率越低。Objective To observe the sensitivity of serum suPAR levels on evaluation the clinical features in idiopathic FSGS patients. Methods Idiopathic FSGS patients were retrospective analyzed, serum suPAR levels were measured by ELISA, the association of serum suPAR levels with the clinical features of FSGS patients was observed. Results Nephritic syndrome as the main performance in idiopathic FSGS patients,who were mostly during 51 to 60 years old（22.8% ）. Serum suPAR levels range from 239 pg/ml to 4 458 pg/ml and with the higher level in more than 40 years old. Serum suPAR levels were negatively correlated with total cholesterol by spearman analysis, and it was independently associated with the complete remission rate by the logistic regression analysis. Conclusion Nephritic syndrome is the main performance in idiopathic FSGS. Serum suPAR levels were negatively correlated with total cholesterol. The higher the level of suPAR, the worse the complete remission rate is.

关 键 词：可溶性尿激酶型纤溶酶原激活剂受体 局灶节段性肾小球硬化 肾脏病理 

分 类 号：R692.6[医药卫生—泌尿科学]